The Harbor Health Care ETF returned 15.30% in the second quarter of 2026, led by strong gains in biotechnology stocks fueled by clinical data and merger activity. Pharmaceutical stocks lagged due to the ETF's lower exposure to Eli Lilly, a major benchmark component. Looking ahead to Q3, the outlook for mergers and acquisitions in biopharma is even more positive, suggesting continued potential growth in this sector.
Eli Lilly (LLY) trades at USD 1,147.39 with a 1-day gain of 0.85% as of Sep 15, 2026 15:21 WIB on Pluang. The Harbor Health Care ETF's Q2 2026 return of 15.30% contrasts with its lower exposure to Eli Lilly, a major benchmark stock. This dynamic highlights the ETF's focus on biotechnology stocks, which drove its strong quarterly performance.
Eli Lilly's stock fell 8.44% in the past month despite strong business growth, driven by concerns over pricing and acquisition charges. The company leads the obesity and diabetes market with blockbuster drugs Mounjaro and Zepbound, generating $14.9 b...
August's inflation report showed headline inflation steady and core inflation falling to its lowest in over five years, signaling easing price pressures. Despite this positive data, the Federal Reserve is still expected to raise interest rates to con...
The iShares U.S. Pharmaceuticals ETF (IHE) provides focused exposure to the US pharmaceutical sector, heavily weighted towards Johnson & Johnson and Eli Lilly. It benefits from growth drivers like obesity therapies and strong drug pipelines but carri...
Eli Lilly has finalized its acquisition of AtaiBeckley, a clinical-stage biopharmaceutical company focused on developing rapid-acting neuroplastogens for mental health, including treatment-resistant depression. This acquisition aims to introduce inno...
Eli Lilly and NVIDIA both reported strong quarterly results, with Lilly growing 47.7% driven by obesity drugs Mounjaro and Zepbound, and NVIDIA soaring 105.8% on AI data center demand. Lilly focuses on expanding its pharmaceutical portfolio and manuf...
